Halozyme Therapeutics Quarterly Cash Flow Statement
NASDAQ: HALOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Halozyme Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Halozyme Therapeutics generated $240.9 million of operating cash flow and spent $4.2 million on capital expenditures. That left free cash flow of $236.7 million, a free-cash-flow margin of 49.2% of revenue. Free cash flow was up 141.2% from the prior year's $98.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Halozyme Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 229.91M | 150.05M | -141.59M | 175.22M | 165.16M | 118.09M | 137.01M | 137.01M | 93.25M | 76.82M | 85.39M | 81.84M |
| Net Income growth (YoY) | +39.21% | +27.06% | -203.34% | +27.89% | +77.12% | +53.72% | +60.46% | +67.42% | +24.74% | +93.92% | +47.98% | +32.78% |
| Depreciation & Amortization | 4.50M | 4.22M | 3.30M | 2.70M | 2.70M | 2.69M | 2.65M | 2.60M | 2.60M | 2.44M | 2.93M | 2.70M |
| Stock-Based Compensation | 17.70M | 16.64M | 16.57M | 12.16M | 12.16M | 10.67M | 11.46M | 12.58M | 9.47M | 9.87M | 9.66M | 9.37M |
| Change in Working Capital | -43.56M | -26.20M | -9.43M | -58.28M | -92.02M | 7.47M | 25.37M | -53.94M | -82.26M | 21.55M | -23.52M | 21.91M |
| Operating Cash Flow | 240.89M | 180.08M | 219.03M | 178.60M | 99.71M | 154.22M | 178.47M | 115.38M | 55.79M | 129.43M | 102.35M | 132.41M |
| Capital Expenditures | -4.17M | -3.74M | -1.43M | -3.03M | -1.56M | -950.00K | -3.05M | -1.52M | -2.58M | -3.54M | -2.60M | -2.94M |
| Investing Cash Flow | -62.66M | -2.88M | -741.79M | 201.61M | 84.79M | -90.42M | 29.48M | -167.48M | -42.04M | -82.68M | -8.29M | -83.45M |
| Share Repurchases | — | — | 0 | -38.88M | — | — | -250.00M | 0 | 0 | 0 | -252.30M | 0 |
| Debt Issued | — | — | — | — | — | — | — | — | — | — | — | 0 |
| Financing Cash Flow | -326.25M | -1.61M | 239.51M | -22.40M | -298.97M | -3.32M | -246.41M | 18.56M | 9.48M | -489.00K | -249.92M | 4.10M |
| Net Change in Cash | -148.02M | 175.59M | -283.24M | 357.80M | -114.47M | 60.48M | -38.47M | -33.55M | 23.24M | 46.26M | -155.86M | 53.06M |
| Free Cash Flow | 236.72M | 176.34M | 217.60M | 175.57M | 98.15M | 153.27M | 175.41M | 113.86M | 53.21M | 125.88M | 99.76M | 129.47M |
This table shows 12 quarterly periods of Halozyme Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow HALO's reporting calendar. What is a cash flow statement?